Shortening of cardiac action potentials in endotoxic shock in guinea pigs is caused by an increase in nitric oxide activity and activation of the adenosine triphosphate-sensitive potassium channel

Citation
Cc. Chen et al., Shortening of cardiac action potentials in endotoxic shock in guinea pigs is caused by an increase in nitric oxide activity and activation of the adenosine triphosphate-sensitive potassium channel, CRIT CARE M, 28(6), 2000, pp. 1713-1720
Citations number
67
Categorie Soggetti
Aneshtesia & Intensive Care
Journal title
CRITICAL CARE MEDICINE
ISSN journal
00903493 → ACNP
Volume
28
Issue
6
Year of publication
2000
Pages
1713 - 1720
Database
ISI
SICI code
0090-3493(200006)28:6<1713:SOCAPI>2.0.ZU;2-6
Abstract
Objective: To investigate the roles of nitric oxide and adenosine triphosph ate (ATP)-sensitive potassium channels (KATP) in the shortening of cardiac action potential in endotoxic shock. Design: Prospective animal study with concurrent controls. Setting: University animal research laboratory. Subjects: Adult Hartley guinea pigs, weighing 300-400 g. Interventions: Guinea pigs were anesthetized and mechanically ventilated fa r 6 hrs. Lipopolysaccharide (LPS) or saline (sham group) were given intrave nously. Drug effects were examined at the end of 6 hrs. Measurements and Main Results:Plasma nitrate concentration was measured hou rly, while guanosine 3',5'-cyclic monophosphate (cGMP) content and action p otential duration at 90% of repolarization (APD(90)) of papillary muscle we re examined every 2 hrs in Be 6-hr endotoxemia in both the sham and the LPS -treated groups. The basal levels of these three variables showed no differ ence in the two groups. In the sham group, these variables did not change s ignificantly (n = 14 for plasma nitrate determination; n = 5 for cGMP conte nt measurement; n = 5-14 for APD(90) measurement; all p > .05). But in the LPS-treated group, both plasma nitrate concentration and cGMP content of pa pillary muscle showed time-dependent increases and they were significantly higher than those in the sham group (at the 6th hr, plasma nitrate: 42.6 +/ - 7.7 vs. 21.8 +/- 3.1 mu mol/L, both n = 14, p < .01; cGMP: 1.52 +/- 0.15 vs. 0.73 +/- 0.08 pmol/mg protein, both n = 5, p < .01). In contrast APD(90 ) revealed a time-dependent decrease compared with that in the sham group ( at the 6th hr, 137.1 +/- 5.2 vs. 188.2 +/- 4.8 msecs, both n = 14, p < .001 ). In the following 60-min in vitro recording of action potentials after th e end of 6-hr endotoxemia, the shortened APD(90) in the LPS-heated group di d not recover and remained shorter compared with that in the sham group, in which the APD(90) showed no significant changes (at the 60th min, 165.1 +/ - 5.7 vs. 200.2 +/- 3.8 msecs, each n = 14 p < .01). However, in the presen ce of glibenclamide, a specific KATP blocker (100 mu mol/L; n = 10), the AP D(90) could be reversed almost completely to the same value as that in the sham group (n = 14) (196.6 +/- 3.5 vs. 200.2 +/- 38 msecs; p > .05), despit e glibenclamide having no effect on the APD(90) in the sham group. In the L PS-treated group, NG-nitro-L-arginine methyl ester (1 mmol/L; n = 4), methy lene blue (10 mu mol/L; n = 5), and aminoguanidine (100 mu mol/L; n = 4) si gnificantly prolonged the shortened APD(90) (192.5 +/- 3.1, 195.0 +/- 3.3, and 176.5 +/- 3.3 msecs, respectively; p < .01, p < .01, and p < .05, respe ctively, compared with that without these agents, 165.1 +/- 5.7 msecs, n = 14). These agents had negligible effects an the APD(90) in the sham group ( all p > .05). Furthermore, 8-bromoguanosine-3',5'-cyclic monophosphate (500 mu mol/L; n = 5) decreased APD in intact papillary muscle (mean reduction of APD(90), 13.5 +/- 3.5%, n = 5; p < .05), an effect abolished by pretreat ment with glibenclamide (100 mu mol/L; n = 5) that did not have an effect b y itself. Conclusions: In this experimental model, we provide reasonably convincing e vidence to suggest that in endotoxic shock, an increase in nitric oxide act ivity may activate KATP, which plays a major role in the shortening of APD, presumably through a cGMP-dependent pathway.